Skip to main content

6 Result(s)

within Annemilaï Tijeras-Raballand Remove this filter

and

  1. No Access

    Article

    Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8+ Lymphocyte Repopulation in Hepatocellular Carcinoma

    Palmitoyl-protein thioesterase-1 (PPT1) is a clinical stage druggable target for inhibiting autophagy in cancer.

    Eloïne Bestion, Madani Rachid, Annemilaï Tijeras-Raballand, Gael Roth… in Targeted Oncology (2024)

  2. No Access

    Chapter

    Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine Tumors (PNETs) Treatment

    Chemotherapy in pancreatic neuroendocrine tumors (PNET) has remained for decades the only validated therapeutic option, albeit with debated efficacy. Recently, data from two large placebo controlled phase III...

    Annemilaï Tijeras-Raballand, Cindy Neuzillet… in Management of Neuroendocrine Tumors of the… (2014)

  3. No Access

    Article

    Stromal expression of SPARC in pancreatic adenocarcinoma

    Pancreatic ductal adenocarcinoma (PDAC) stands as the poorest prognostic tumor of the digestive tract, with a 5-year survival rate of less than 5 %. Therapeutic options for unresectable PDAC are extremely limi...

    Cindy Neuzillet, Annemilaï Tijeras-Raballand, Jérôme Cros… in Cancer and Metastasis Reviews (2013)

  4. No Access

    Article

    Targeting the Ras–ERK pathway in pancreatic adenocarcinoma

    Pancreatic ductal adenocarcinoma (PAC) stands as the poorest prognostic tumor of the digestive tract with limited therapeutic options. PAC carcinogenesis is associated with the loss of function of tumor suppre...

    Cindy Neuzillet, Pascal Hammel… in Cancer and Metastasis Reviews (2013)

  5. No Access

    Article

    Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models develo** resistance to sunitinib and sorafenib

    To evaluate first-generation rapamycin analogs (everolimus, temsirolimus, and rapamycin) and second-generation drugs inhibiting mTOR kinase (AZD-8055), PI3K (BKM-120) or both (BEZ-235 and GDC-0980) in hepatoce...

    Maria Serova, Armand de Gramont… in Cancer Chemotherapy and Pharmacology (2013)

  6. No Access

    Article

    Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies

    Management of advanced pancreatic neuroendocrine tumors (PNETs) is challenging. Chemotherapy has remained for decades the only validated therapeutic option, with debated efficacy. Recently, data from two large...

    Annemilaï Tijeras-Raballand, Cindy Neuzillet, Anne Couvelard… in Targeted Oncology (2012)